AQA
VIVO

Alpha Quant Advisors’s Meridian Bioscience Inc VIVO Stock Holding History

Alpha Quant Advisors’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$8K Hold
469
– – 0.01% 268
2018
Q4 		$8K Buy
+469
New +$8K 0.01% 276

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Alpha Quant Advisors's VIVO Position: Q1 2019 in Review

Alpha Quant Advisors held its Meridian Bioscience Inc (VIVO) position steady in Q1 2019 at 469 shares worth $8K. The position accounts for 0.01% of the portfolio, ranked #268.

Alpha Quant Advisors first reported a position in VIVO in Q4 2018 and has held it in 2 quarters since. 183 funds tracked by Wall St. Rank hold VIVO as of Q1 2019.

  • Alpha Quant Advisors held 469 shares of Meridian Bioscience Inc worth $8K as of Q1 2019.
  • Alpha Quant Advisors left its Meridian Bioscience Inc share count unchanged in Q1 2019.
  • Meridian Bioscience Inc made up 0.01% of Alpha Quant Advisors's portfolio in Q1 2019, its #268 holding.
  • Alpha Quant Advisors first reported a position in Meridian Bioscience Inc in Q4 2018 and has held it in 2 quarters since.
  • 183 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2019.

Based on Alpha Quant Advisors's 13F filing for Q1 2019, filed 8 May 2019.